secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001171843-25-002669
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst appoints Steve Frank to board; board size increased to 11
------------------------------------------------------------------

- Steven Frank elected to board effective May 2, 2025, filling new seat after board expansion from 10 to 11 directors.
- Frank is chairman of global healthcare investment banking at J.P. Morgan; previously at Bear Stearns.
- Initial equity grant of $500,000 (60% options, 40% RSUs), prorated from effective date to 2025 annual meeting.
- Frank brings healthcare M&A and capital allocation expertise as BioCryst approaches profitability.
- Frank's term expires at 2027 annual meeting; no committee assignments initially.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184325002669/0001171843-25-002669-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184325002669/f8k_050125.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-002669

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer